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1999). ECM remodeling in vascular wall or perivascular stroma 
involves several enzymes among which Matrix metalloproteases 
(MMPs) produced by endothelial, inflammatory, or malignant cells 
are key players. MMPs are a family of zinc endopeptidases com-
posed of 24 currently known human enzymes that share several 
functional domains. MMPs are often referred to soluble (MMPs) 
or membrane type-MMPs (MT-MMPs) that are anchored to the 
cell surface through transmembrane domain or glycosylphos-
phatidylinositol (GPI) linker. For a description of the structure, 
function, and regulation of MT-MMPs, the reader is referred to 
previous reviews (Sounni and Noel, 2005; Sohail et al., 2008). 
MT1-MMP (membrane type 1-matrix metalloproteinase-1, also 
known as MMP-14) a MMP with transmembrane and cytoplasmic 
domains is a unique cell surface activator of pro-MMP2 through 
the formation of trimolecular complex with TIMP-2 (tissue inhib-
itor of metalloproteinases). In addition, MT1-MMP has a large 
number of substrates including ECM and non-ECM molecules 
(Figure 1). MT4-MMP however has a glycophosphatidylinositol 
anchor instead of the type-1 transmembrane and is a poor activator 
of pro-MMP2. Despite the high degree of similarity between its 
ectodomain structure and that of MT1-MMP, MT4-MMP has a 
restricted repertoire of substrates with no activity against collagens 
(Figure 1). Collagenases are the only known mammalian enzymes 
able of degrading triple-helical fibrillar collagen into distinctive 3/4 
and 1/4 fragments. Collagenolytic MMPs including MMP1, MMP8, 
MMP13, MMP14/MT1-MMP play pivotal roles in multiple physi-
ological and pathological processes involving extensive and aber-
rant collagenolysis. MMP-mediated collagen remodeling regulates 
tissue homeostasis and development through several mechanisms, 
such as the generation of space for cell migration, production of 
cryptic peptides with novel biological activity or activation of 
signaling molecules (Page-McCaw et al., 2007). Latest techno-
logical progresses have obviously advanced our consideration of 
IntroductIon
In cancer, the extracellular matrix (ECM) within and surround-
ing a tumor undergoes continuous remodeling. It differs from 
that of normal tissue, and consequentially influences vascular cell 
behaviors (DeClerck et al., 2004). Tumor blood vessels are tor-
turous, irregular in dimension and shape, and lack the hierarchi-
cal organization of arterioles, capillaries, and venules as found in 
normal vessels (Baluk et al., 2005). The endothelium of tumor 
vessels contains large number of fenestrations and the basement 
membrane surrounding vessels has altered morphology due to 
extensive vessel remodeling. Altered blood vessel structure causes 
disorganized blood flow within the tumor and increased leakage 
that lead to increased interstitial fluid pressure (IFP) Baluk et al., 
2005). Enhanced IFP in the tumor interstitium results not only, 
from leaky blood vessels but also from dysfunctional lymphatics. 
Such an increased IFP forms a barrier for transcapillary transport 
and represents a potential obstacle to the delivery of therapeutic 
molecules (Heldin et al., 2004; Wiig et al., 2010). Many current anti-
cancer agents are not able to disseminate through tumors because 
of the high intratumoral IFP. Recently, the normalization of tumor 
vessels emerged as a new challenge for anti-angiogenic therapy and 
is now recognized as a requisite step to improve delivery of cytotoxic 
drugs inside tumors (Jain, 2005).
The ECM in the vascular wall contains a variety of molecules 
including collagens, elastic fibers, hyaluronan (HA), fibronectin, 
vitronectin, laminins, glycosaminoglycans (GAG), proteoglycans, 
and adhesive glycoproteins that provide structural and mechanical 
support to the cells. Vascular and perivascular cells are connected 
to major structural ECM components by cell surface receptors 
including integrin and non-integrin molecules (Kalluri, 2003; 
Davis and Senger, 2008). Interactions of these receptors with 
ECM molecules influence vascular cell shape, behavior, and the 
response to cytokines and growth factors (Boudreau and Jones, 
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MMPs as important modulators of the tumor microenvironment 
(Kessenbrock et al., 2010). Beside their capacity to remodel ECM, 
these enzymes mediate the release of ECM-associated growth fac-
tors such as VEGF, TGFβ as well as unmask cryptic sites within ECM 
molecules which can simulate malignant cells and endothelial cells 
to communicate and escape from homeostatic control (Rundhaug, 
2005; Page-McCaw et al., 2007; Kessenbrock et al., 2010). However, 
the contribution of MMPs to vessel maturation and stabilization is 
an innovative emergent concept. Understanding the complex roles 
of MT-MMPs in vessel wall assembly and function in homeostasis 
or disease will open new avenues to maintain vessel stability and 
functionality. The present review will highlight the emerging roles 
of MT1-MMP and MT4-MMP in vascular cell fate and function 
during cancer progression.
collagen proteolysIs In perIvascular stroma
Collagen is the most abundant molecule of the ECM. It includes 
fibrillar collagen types I, II, and III, with type I collagen repre-
senting the major type within ECM stroma, with 25% of total 
protein in the body (Shoulders and Raines, 2009). Initial studies 
examining the role of type I collagen in new blood vessel function 
started 28 years ago. Montesano et al. (1983) have demonstrated 
that, when cultured in vitro within 3D matrix of type I collagen, 
endothelial cells reorganize into capillary-like structures. Later, 
different studies revealed that the interaction between endothe-
lial cells and type I collagen is mediated by several β1 integrins 
including α1β1, α2β1, and α3β1 (Xu et al., 2000). Moreover, inhi-
bition of integrin α1β1 and α2β1 either by blocking antibody 
or silencing by small interferon RNA, disrupts VEGF signaling 
and inhibits endothelial cell migration and tumor angiogenesis 
(Senger et al., 2002).
Type I collagen is cleaved into characteristic 3/4 and 1/4 frag-
ments by collagenolytic MMPs, including MMP1, MMP8, MMP13, 
and MT1-MMP (Ohuchi et al., 1997). Among the collagen remod-
eling enzymes, MT1-MMP-mediated cleavage of type I collagen 
stimulates migration, guidance, and organization of endothelial 
cells to form tubular structures (Chun et al., 2004). Type I collagen 
remodeling by MT1-MMP during tumor growth has been demon-
strated by the study of Hotary et al. (2003) showing that MT1-MMP 
expression in cancer cells enables these cells to escape the mechani-
cal barriers that confine them to collagen matrix and stimulates 
tumor growth in vivo. Moreover, the generation of Mt1-mmp−/− 
mice pinpointed the role of MT1-MMP in collagen remodeling 
during embryonic and post-natal development growth. Indeed, 
Mt1-mmp−/− mice exhibit skeletal defects with craniofacial abnor-
malities, osteopenia, and angiogenesis (Holmbeck et al., 1999; Zhou 
et al., 2000). MMP2 is activated primarily by MT1-MMP present 
at the cell surface. Although MMP2 exhibits mainly a gelatinolytic 
activity, it is able to cleave type I collagen by a mechanism distinct 
from the classic collagenases (Tam et al., 2004). MMP2 emerged as 
a new collagenase with higher activity against type I collagen har-
boring a mutation that renders it resistant to collagenase-mediated 
cleavage to 3/4 and 1/4 fragments (Col1a1r/r ) than the normal 
type I collagen (Egeblad et al., 2007). Interestingly, the generation 
of Mmp2−/− mice with similar mutation in colla1 gene (Mmp2−/−; 
Col1a1r/r mice) showed severe skeletal defects and developmental 
abnormalities resembling those observed in MMP2-null humans 
and those seen in Mt1-mmp−/− mice (Egeblad et al., 2007). While 
Mmp2−/− mice develop normally with no major skeletal abnormali-
ties, the perturbation of collagen degradation in vivo increases the 
phenotypic alteration, suggesting that MMP2 is important for type 
I collagen remodeling during development.
Type I collagen remodeling in perivascular stroma represents 
an important step for endothelial cell reorganization into tubular 
structures during normal and pathological angiogenesis. In addi-
tion, a direct link between collagen metabolism and the regulation 
of vascular leakage has been demonstrated in transgenic Col1a1r/r 
mice with collagenase-resistant collagen (Liu et al., 1995). The 
steady-state vascular leakage is dramatically reduced in these mice. 
Furthermore, the evaluation of acute vascular leakage in response to 
tissue assault revealed a failure to develop normal vascular response 
to tissue injuries and damage due to reduction of vascular openings 
within vessel wall in these transgenic mice (Sounni et al., 2010a). 
In cancer, collagen cross-linking and stiffening is known to induce 
malignant progression through integrin clustering and signaling, 
activation of focal adhesion kinase (FAK), PI3 kinase, and Akt 
(Levental et al., 2009). However, the effect of collagen abundance 
and cross-linking on endothelial cell behaviors and its effect on 
signaling and leakage in tumor vessels remain to be explored.
Vascular leakage and ECM remodeling are considered as a criti-
cal and requisite step in angiogenesis initiation in response to tissue 
damage, wound repair, or tumor. It is recognized that collagen 
architecture controls the diffusion and transport of macromol-
ecules in tissue. A genetic alteration of ECM structure in the vessel 
wall impacts blood vessel integrity and the extravasation of fluids 
Figure 1 | Structure and substrate specificity of MT1-MMP and 
MT4-MMP. The structure of MT1-MMP and MT4-MMP share the identical 
domain organization of most MMPs, including a signal sequence (SS), 
propeptide domain (pro), a zinc-containing catalytic domain (catalytic) with 37 
identity (50% similarity), a hing region, and a hemopexin like domain 
(hemopexin). In addition, MT1-MMP and MT4-MMP are anchored to the cell 
surface through a hydrophobic a transmembrane domain (TM) and a GPI 
anchor, respectively. Both the transmembrane MT1-MMP and the GPI–MT4-
MMP contain proprotein convertase recognition RXR/KR motif in the 
propeptide domain and a hydrophilic region also called stem region at the end 
of hemopexin like domain. Whereas MT1-MMP exhibits activity against many 
ECM and non-ECM components both in vitro and in vivo, MT4-MMP was 
found in vitro to have a minimal or no activity against ECM molecules. The 
substrates of MT4-MMP in vivo are not yet identified.
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several proteases of the MMP family membrane to activate recep-
tor tyrosine kinase (RTK) that may promote pericyte recruitment 
and vessel maturation in vivo (Eguchi et al., 2001). For instance, 
MMP3 cleavage of proHB–EGF at specific juxtamembrane site 
enhances growth factor bioavailability in physiological and path-
ological processes (Suzuki et al., 1997), CD44 mediates MMP7/
proHB–EGF complex formation and active HB–EGF release (Yu 
et al., 2002). MMP2 and MMP9 contribute to EGFR activation 
in vivo in a mouse model of pressure-induced myogenic tone of 
resistance arteries (Lucchesi et al., 2004). In several tumor models, 
MMPs have been shown to release soluble factors sequestered in 
the ECM and regulate vascular cell formation and maturation. For 
instance, inflammatory cell-derived MMP9 promotes tumor angio-
genesis through the release of ECM-bound angiogenic factor such 
as VEGF (Bergers et al., 2000; Huang et al., 2002). Furthermore, 
in vitro, MMP2, MMP3, and MMP7 induce the release of TGFβ1 
from decorin, a proteoglycan that sequester TGFβ in the matrix 
(Imai et al., 1997).
In addition to these multiple actions of soluble MMPs, these 
enzymes also contribute to the selective recruitment of bone 
marrow-derived stem cells occurring in post-natal organogen-
esis and tumorigenesis (Coussens et al., 2000; Lyden et al., 2001). 
Recruitment of hematopoietic stem cells (HSCs), but also other 
types of undifferentiated cells, such as endothelial progenitor cells 
(EPCs) seem to be dependent on proteolytic activation of their 
effector cytokines. MMP9 has been identified as a key player in 
mobilization of both HSCs and VEGFR2+ CEPs to the circula-
tion from BM. In this context, MMP9 converts Kit-ligand from a 
membrane-bound molecule to a soluble survival/mitogenic factor 
sKit-ligand (Heissig et al., 2002). MMP2 and MMP9 can play a 
major role in EPCs migration and vessel maturation during several 
physiological processes. Yoon et al. (2005) have isolated and charac-
terized early EPCs and late outgrowth endothelial cells (OECs) for 
their angiogenic potential and demonstrate that MMP9 and MMP2 
secretion by both EPCs and OECs are essential for maturation and 
repair during ischemia. However, the contribution of EPCs to the 
angiogenic process during cancer development or their implication 
in vessel maturity is still not clear. Recently, Purhonen et al. (2008) 
have provided evidences that EPCs are not required for tumor 
angiogenesis. Another study has proven that hematopoietic cells 
infiltrating tumors are not EPCs but rather CD11b-positive myelo-
monocytic cells. Furthermore, these cells are likely responsible for 
tumor vasculogenesis but not angiogenesis, their recruitment to 
tumor is dependent on MMP9 expression (Ahn and Brown, 2008). 
Despite, their role in angiogenesis, soluble MMPs are also important 
in vascular homeostasis. For instance, MMP9 plays an important 
role in edema prevention. Experimental secondary lymphedema 
in the mouse tail of MMP-9 null mice were unable to sufficiently 
counteract the swelling due to the lack of matrix remodeling around 
lymphatic vessels (Rutkowski et al., 2006).
All together, soluble MMPs might participate in vessel matura-
tion through the control of bioavailability of growth factors and 
cytokines that regulate pericyte recruitment and coverage of new 
formed vessels in solid tumors. However, it cannot be excluded 
that one or a group of these soluble MMPs acting in perivascular 
stroma or in the vessel wall, deregulates vessel permeability and 
contributes to pathological vascular leakage associated with cancer.
and plasma proteins (Wiig et al., 2008). Collagen accumulation 
together with proteoglycans and myofibroblasts in the interstitial 
space contributes also to the higher IFP observed in solid tumors 
which regulates drug diffusion through the tumor (Heldin et al., 
2004). Thus, perivascular ECM emerged recently as an important 
determinant of intratumoral IFP and a drug delivery modulator 
(Netti et al., 2000). In tumor stroma, increased collagen synthe-
sis and accumulation are correlated to restrictive delivery of high 
molecular weight anti-cancer drugs (Netti et al., 2000; Brown et al., 
2003). Furthermore, enzymatic digestion of collagen and decorin, 
an associated proteoglycan, improves macromolecule diffusion 
inside tumors (Magzoub et al., 2008). In addition, a major con-
sequence of macrophage and other inflammatory cell infiltration 
into the tumor stroma is the release of cytokines and growth factors 
which, by acting on stromal fibroblasts and blood vessels, stimulate 
the production of ECM molecules, further reinforcing matrix accu-
mulation and IFP enhancement within tumors (Heldin et al., 2004). 
One of the clinical impacts of the control of collagen remodeling 
in perivascular stroma would be to normalize tumor vasculature, 
lower IFP, and modulate hydraulic conductivity of the stroma and 
fluid balance. Consequently, this would improve tumor perfusion 
and delivery of cytotoxic drugs in solid tumors (Kessenbrock et al., 
2010; Sounni et al., 2010a).
soluble mmp In vessel maturatIon
Perturbations of tumor blood vessels have been attributed to their 
failure to mature and to restore quiescence as normal vessels. 
Among the vascular cells, pericytes are major players contributing 
to vessel maturation (Feron, 2004). Due to their contractile activity, 
pericytes control the blood flow in normal and tumor vessels and 
consequently, regulate drug delivery into tumor tissue (Feron, 2004; 
Raza et al., 2010). The pericyte recruitment around endothelial 
cells during embryonic development, atherosclerosis, and tumor 
angiogenesis relies on different pathways which involve PDGFB/
PDGFR-β, sphingosine 1-phosphate (S1P)/endothelial differentia-
tion gene-1 (EDG-1), Ang1/Tie-2, and TGF-β/activin-like kinase 
receptor (ALK5) axis (Jain, 2003; Gerhardt and Semb, 2008; Park 
et al., 2009). For instance, genetic ablation of PDGFB or PDGFR-β 
in mice is associated with a lack of pericyte coverage around vessels 
and lead to microvascular aneurysms and lethal microhemorrhages 
(Lindahl et al., 1997). Beside the role of growth factors in peri-
cyte recruitment and vessel maturation, soluble MMPs are known 
to facilitate pericyte migration and vessel coverage (Sounni and 
Noel, 2005; Chantrain et al., 2006). MMP inhibition in different 
experimental tumor models of melanoma and neuroblastoma show 
reduced pericyte recruitment and decreased tumor vessel perfusion 
(Spurbeck et al., 2002; Chantrain et al., 2004; Noel et al., 2008). 
Among soluble MMPs, MMP9 is considered as the most impor-
tant candidate in pericyte recruitment from bone marrow. Pericyte 
coverage along tumor microvessels is decreased in Mmp9−/− mice 
xenotransplanted with human neuroblastoma. Indeed, the forma-
tion of mature tumor vessels is restored when Mmp9−/− mice are 
transplanted with bone marrow from wild type mice (Chantrain 
et al., 2004). In addition, MMPs increase the bioavailability of 
factors that affect pericyte phenotype through the activation and 
release of growth factor from cell surface or ECM. Among these 
factors, HB–EGF shedding from cell membrane is mediated by 
Sounni et al. MT-MMPs regulate vessel stability
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induces VSMC dedifferentiation and acquisition of migratory and 
invasive phenotype during vascular injury through low density 
lipoprotein (LDL) receptor-related protein (LRP) proteolysis that 
promotes signaling through PDGFB/PDGFR-β axis (Lehti et al., 
2009). Indeed, MT1-MMP cooperates with platelet derived S1P 
to induce endothelial cell migration and morphogenic differen-
tiation (Langlois et al., 2004). Furthermore, MT1-MMP regulates 
signaling of the advanced glycation end products (AGE)/a receptor 
for AGE (RAGE) axis in the vasculature, a target known to play a 
key role in diabetic vascular complications (Kamioka et al., 2011). 
Interestingly, expression of MT1-MMP correlates with the clini-
cal mobilization of human CD43+ cell in patient with lymphoid 
malignancies (Vagima et al., 2009). Of interest, MT1-MMP expres-
sion and its association with lipid rafts facilitates G-CSF-induced 
hematopoietic stem/progenitor cell (HSPC) mobilization in human 
and murine (Shirvaikar et al., 2010). The molecular mechanisms 
of MT1-MMP relay on CD44 cleavage, activation of pro-MMP2 
and inactivation of SDF-1 that facilitates HSPC egress from the 
bone marrow into circulation (Shirvaikar et al., 2011). MT1-MMP 
signaling in cancer cells, pericytes, and endothelial cells are sche-
matically illustrated in Figure 2.
Recently, a spatial and temporal expression of MT1-MMP 
during angiogenesis has been monitored in the transgenic Mt1-
mmp+/LacZ mice (Yana et al., 2007). This study shows that vas-
cular maturation coordinated by crosstalk between endothelial 
cells and VSMC reorients MT1-MMP expression at leading edges 
of newly developed vessels. Implication of MT1-MMP in ves-
sel stabilization/destabilization has been reinforced by the study 
of Onimaru et al. (2010) which reveals an interaction between 
MT1-MMP and angiopoietin (Ang)–Tie-2 axis. It is well known 
that VEGF regulates Ang–Tie-2 signaling by inducing proteolytic 
cleavage and shedding of Tie-2 (Findley et al., 2007). MT1-MMP 
has been recently shown to induce shedding of Tie-2 from cul-
tured endothelial cells and modulates Ang1-dependent Tie-2-
associated signaling pathways (Onimaru et al., 2010). MT1-MMP 
activity leads to a Tie-2 shedding-mediated decrease in endothelial 
Tie-2 level, resulting in the induction of vessel destabilization and 
subsequent endothelial migration. Although the role of Ang–Tie-2 
signaling in vascular growth and remodeling is quite complex, 
it is generally accepted that Ang1-mediated activation of Tie-2 
promotes vascular stabilization and quiescence, whereas Ang2 
acts in opposition to Ang1 to facilitate VEGF mediated angio-
genesis. The role of MT1-MMP in Ang2–Tie-2 signaling is still 
not investigated and, whether MT1-MMP activity is required for 
vessel maturation step Ang–Tie-2 dependent pathway in pericyte 
are required to define the precise role of this enzyme during all 
angiogenesis steps.
We recently investigated MT1-MMP activity in perivascular 
stroma and the regulation of vascular permeability in vivo (Sounni 
et al., 2010a). We directly assessed whether MMP inhibition in both 
healthy and mouse model of age-related dermal fibrosis (i.e., Col1a1r/r 
mice Liu et al., 1995) could impact vascular leakage in an in vivo 
vascular leakage assay (Miles and Miles, 1952). Surprisingly, prior 
treatment with broad spectrum MMP inhibitor GM6001 (Ilomastat, 
Galardin) significantly increases vascular leakage in both wild type 
and Col1a1r/r mice. This indicates that the inhibition of steady-state 
MMP activity renders vessels more susceptible to induced acute 
role of mt1-mmp In vessel maturatIon
The contribution of MT1-MMP in angiogenesis is well docu-
mented and reported in the literature (Lafleur et al., 2003; Sounni 
et al., 2003; Zucker et al., 2003; Stratman et al., 2009). MT1-MMP 
is likely the most important MMP regulating endothelial cell func-
tions. The generation of Mt1-mmp mice has shed light on the key 
role played by MT1-MMP during angiogenesis (Zhou et al., 2000; 
Sounni and Noel, 2005). MT1-MMP stimulates angiogenesis in 
fibrin gel more efficiently than serine, cysteine proteases, and other 
MMPs (Hiraoka et al., 1998; Hotary et al., 2002; Collen et al., 2003). 
The proangiogenic mechanisms of MT1-MMP include: (1) cleav-
age of ECM molecules, (2) the production of angiogenic factors, 
such as VEGF, (3) interaction with cells surface molecules, such 
as CD44 and S1P, (4) the degradation of anti-angiogenic factors 
such as decorin in cornea (Mimura et al., 2009). These regulatory 
mechanisms could enhance angiogenesis in both physiological 
and pathological conditions. Alternatively, additional signaling 
molecules, such as proTGFβ and endoglin (TGFβ receptor) are 
substrates of MT1-MMP, which can play a dual role on vessel matu-
ration and angiogenesis.
We and others have previously demonstrated that MT1-MMP 
overexpression in cancer cells stimulates tumor angiogenesis in vivo 
through VEGF upregulation (Deryugina et al., 2002; Sounni et al., 
2002, 2004; Deng et al., 2009). MT1-MMP regulation of VEGF 
expression is dependent on Src signaling and requires the proteo-
lytic activity of MT1-MMP (Sounni et al., 2004). Recently, Eisenach 
et al. (2010) have provided a complete mechanism of VEGF regula-
tion by MT1-MMP and Src signaling. This study demonstrates that 
MT1-MMP regulates VEGF through a complex with VEGFR-2 and 
Src, activation of Akt and mTOR signaling pathway. MT1-MMP 
activity and signaling through cytoplasmic domain are confirmed 
as required for transcriptional regulation of VEGF expression in 
cancer cells. MT1-MMP interaction with Src has also been investi-
gated in several in vitro models of angiogenesis and cell migration 
(Labrecque et al., 2004; Ouyang et al., 2010; Sabbota et al., 2010). 
MT1-MMP-mediated Src activation has also been described dur-
ing cell migration. Recently, Sabbota et al. (2010) reported that 
MT1-MMP induces receptor activator of NF-κB ligand (RANKL) 
shedding from prostate cancer cell surface and signaling through its 
receptor RANK and downstream Src activation and consequently 
stimulates cell migration. Src activation by MT1-MMP has also 
been linked with ERK1/2 activation in cell migration within 3D 
collagen gel (Takino et al., 2010). However, MT1-MMP can form 
a complex with TIMP2 at the cell surface that can stimulate cancer 
cell migration in a non-proteolytic manner. This non-proteolytic 
mechanism implicates the activation of MEK1/2-ERK1/2-p90RSK 
signaling cascade by the MT1-MMP/TIMP-2 complex (Sounni 
et al., 2010b). Beside its role in ECM remodeling, MT1-MMP pro-
motes endothelial cell migration, lumen formation, and vascular 
guidance tunnels in collagen matrices (Stratman et al., 2009). The 
observation of Lehti et al. (2005) that Mt1-mmp−/− mice present a 
marked reduction in mural cell density and abnormal vessel mor-
phology in brain, suggests that membrane-associated MMP acts 
as a cofactor in propagating signaling through vascular smooth 
muscle cells (VSMC). This study, demonstrates that MT1-MMP 
processing of PDGFR-β is required for PDBFB/PDGFR-β sign-
aling in VSMC and migration in vitro. Moreover, MT1-MMP 
Sounni et al. MT-MMPs regulate vessel stability
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soluble endoglin that acts as decoy for TGFβ and blocks down-
stream signaling in endothelial cells. Although the study shows 
that soluble form of circulating endoglin decreases in colorectal 
cancer patients, it did not correlate this with MT1-MMP levels and 
tumor angiogenesis in patients. The effect of MT1-MMP interac-
tion with TGFβ signaling on angiogenesis in vivo, is a complex 
regulatory mechanism that depends on its spatial distribution, 
such as, perivascular stroma or endothelial cells compartment. A 
direct shedding of endoglin from endothelial cell surface inhibits 
angiogenesis (Hawinkels et al., 2010), but the cleavage of LTBP-1 
(Dallas et al., 2002; Tatti et al., 2008) or LAP–TGFβ from the 
stroma in fibrotic tissue increases TGFβ availability which in turn 
activates TGFβ signaling in vascular cells (Sato, 1995; Sounni 
et al., 2010a).
MT1-MMP/TGFβ signaling axis is regulated by type I collagen, 
the most abundant ECM molecules. Type I collagen induces MT1-
MMP expression which in turn regulates TGFβ signaling in stromal 
and cancer cells (Gilles et al., 1997; Ottaviano et al., 2006; Shields 
et al., 2011). Moreover, a recent report by Dangi-Garimella et al. 
(2011) shows that collagen induces MT1-MMP expression which 
in turn repress tumor suppressor let-7 family of micro RNA expres-
sion in pancreatic ductal adenocarcinoma tumor. Interestingly, the 
mechanism regulated by MT1-MMP in this study is dependent 
on TGFβ signaling and ERK1/2 activation, which is in accordance 
with our previous reports on vessel maturation and cell migra-
tion (Sounni et al., 2010a,b). In contrast, MT1-MMP may play 
leakage, and implies a link between steady-state MMP activity and 
vascular leakage. In vivo vascular assays applied to the skin of differ-
ent MMP-deficient mice such as Mmp2−/−, Mmp9−/−, Mmp8−/−, and 
Mmp13−/− lead to similar results except for Mt1-mmp−/− mice. Mice 
lacking MT1-MMP show a distinct higher steady-state vascular leak-
age and low levels of active TGFβ compared to their corresponding 
age-matched wild type littermates. Maintaining vascular homeos-
tasis relies on molecular mechanisms coordinated by MT1-MMP 
activity which controls TGFβ bioavailability and signaling through 
ALK5 in vascular wall. In vivo inhibition of TGFβ signaling in mice 
treated with small amount of ALK5 inhibitor (ALK5I) for 1 week, 
strongly increases vascular leakage both in normal and fibrotic 
skin, and it also enhances macromolecules delivery in neoplastic 
tissues (Figure 3). The treatment of transgenic mice developing skin 
carcinoma (K14-HPV16 transgenic mice) and mammary adeno-
carcinomas (MMTV-PyMT mice) with ALK5I results in enhanced 
delivery and bio-distribution of macromolecules in tumors com-
pared to mice treated with vehicle alone. Taken together, these data 
provide evidence for a central role for MT1-MMP-activated TGFβ 
in mediating vascular homeostasis and remodeling. They further 
indicate that TGFβ and/or MT1-MMP-selective antagonists may 
enhance vascular leakage and therapeutic delivery to tissues where 
hemodynamic limits efficient drug delivery.
Recent report, by Hawinkels et al. (2010) shows that MT1-
MMP dependent shedding of endoglin inhibits angiogenesis in 
vitro. MT1-MMP activity at endothelial cell surface increases 
Figure 2 | Membrane type-MMPs regulate vascular cell signaling in 
cancer. MT1-MMP regulates cell migration through both ECM proteolysis and 
non-proteolytic-dependent TIMP-2 activation of ERK1/2 pathway. MT1-MMP 
regulates VEGF gene expression through Src, Akt, and mTOR activation and 
stimulates tumor angiogenesis. In addition, it induces RANKL shedding and 
signaling through Src leading to cell migration. MT1-MMP cooperates with 
platelet derived S1P to induce signaling through G protein-coupled-receptors 
(GPCRs) and regulates endothelial cell migration and tubulogenesis. 
MT1-MMP regulates TGFβ bioavailability and its signaling through ALK5 
leading to vessel maturation. Shedding of Tie-2 or degradation of decorin by 
MT1-MMP stimulates angiogenesis, but shedding of endoglin from endothelial 
cell surface inhibits angiogenesis. ProTGFβ can also be activated by MMP2 
and MMP9. MT1-MMP activates PDGFRβ signaling and regulates pericyte 
migration and vessel maturation. MT4-MMP a metastatic MMP, is highly 
expressed by cancer cells and induces tumor vessel destabilization through 
pericyte detachment.
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correlation between the lack of pericyte coverage in tumor and the 
increase of metastatic spread has been attributed to MT4-MMP 
activity in vivo (Chabottaux et al., 2009). The overexpression of 
MT4-MMP in breast cancer MDA-MB-231 cells enhances sub-
cutaneous tumor growth and stimulates the development of lung 
metastases in 100% of inoculated RAG-1 immunodeficient mice 
(Chabottaux et al., 2006). Intriguingly, functional studies failed 
to reveal an effect of MT4-MMP overexpression on in vitro cell 
migration and invasion, pro-MMP2 activation, VEGF production, 
and angiogenesis. The ultrastructural analysis of vessel pericyte 
coverage in tumor overexpressing MT4-MMP by electron micros-
copy revealed unique features of pericytes with irregular shape, 
extended cytoplasm, and poor association with endothelial cells 
(Chabottaux et al., 2009). A computer-assisted quantification con-
firmed a significant detachment of pericytes from vessels in MT4-
MMP overexpressing tumors. The tumor leakiness and delivery of 
high molecular weight compounds were investigated by measuring 
the bio-distribution of fluorescent polymeric macromolecule of 
250 kDa AngioSense 680 into tumor interstitium. MT4-MMP over-
expression confers a significant increase in macromolecule leak-
age into tumors. Furthermore, while MT4-MMP has no effect on 
angiogenic factor expression such as VEGF, TIEs, or PDGFRs and 
their ligands, mRNA expression of the human anti-angiogenic fac-
tor thrombospondin-2 (TSP-2) is modulated in MT4-MMP over-
expressing tumors. These data suggest that MT4-MMP expression 
at tumor cell surface affects vessel integrity and thereafter increases 
vascular leakage and metastatic cell intravasation. Taken together, 
an anti-tumor effect through the induction of cell aggregation 
and Rho-ROCK-Myosin signaling in squamous cell carcinoma or 
keratinocytes (Dangi-Garimella et al., 2010). The formation of cell 
aggregate by MT1-MMP is contradictory to it migration promot-
ing effect widely attributed to this enzyme during the last decade. 
These controversial data require more investigation to determine 
whether MT1-MMP is a pro- or an anti-tumorigenic enzyme and, 
whether these effects are context dependent.
role of mt4-mmp In vessel destabIlIzatIon
The microvessel pericyte coverage in several human tumors and 
their colocalization with endothelial cell markers varied from 10 
to 20% in human glioblastoma and renal carcinoma, to 70% in 
mammary and colon carcinoma (Eberhard et al., 2000). In tumor 
angiogenesis, pericytes contribute to the stabilization of nascent 
microvessels (Raza et al., 2010). They detach from the preexist-
ent vessels and are recruited around the endothelial cell sprouts, 
leading to the reduction of endothelial cell proliferation and the 
formation of larger perfused microvessels (Gee et al., 2003). It is 
possible that tumor cells trigger metastasis through the alteration of 
pericyte-endothelial cell–cell interactions. The recent study by Xian 
et al. (2006) demonstrates that pericytes limit tumor cell metasta-
sis, and the lack or dysfunction of pericytes within tumor vessels 
increases the metastatic potential of solid tumors. Indeed, pancre-
atic beta cell tumorigenesis induced in primary pericyte-deficient 
Pdgfb(ret/ret) mice results in increased tumor cell metastases in 
local lymph nodes and distant organs. In breast carcinoma, the 
Figure 3 | extracellular matrix (eCM) components regulate vascular 
permeability in tumor. Transport of fluids and macromolecules across the vessel 
wall can be regulated by both (1) paracellular diffusion through the apparition of 
openings between vascular cells and (2) transendothelial transport through 
vesiculo-vacuolar organelle (VVO) across the endothelium. Inhibition of ALK5 results 
in increased vascular leakage and increased bio-distribution of macromolecules 
within tumor. Collagen and fibroblast accumulation within tumor opposes to 
macromolecule penetration and reduces drug delivery. Collagen metabolism by 
collagenases results in increased vascular leakage and accumulation of 
macromolecules within tumors. Short inhibition of TGFβ signaling in vascular wall 
and control of the ECM metabolism in perivascular stroma could enhance drug 
delivery in solid tumors (EC, endothelial cell; BM, basement membrane).
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late endothelial cell processes. For example, the RGD tripeptide 
containing domain within the α chain of laminin promotes cell 
adhesion through the binding to β1 integrin. Moreover, a second 
domain (YIGSR) within the β1 chain of laminin induces cell–cell 
interactions, regulates morphogenesis, and reorganizes endothelial 
cells into tube-like structures (Grant et al., 1989). This pentapep-
tide YIGSR sequence binds to endothelial cells via the non-integrin 
laminin receptor (LR; Basson et al., 1990). While many regulatory 
sequences of angiogenesis within laminin are readily available to 
cells, there are also relevant cryptic sequences that require pro-
teolytic remodeling for exposure. For example, the proteolytic 
cleavage of the Laminin-5γ2 chain into several short γ2′ and γ2× 
chains by MT1-MMP and/or MMP2 promotes the formation 
of vasculogenic mimicry formed by tumor cells (Hendrix et al., 
2003). In contrast, laminin α5 chain (component of laminin-10 
and laminin-11) derived peptide (RLVSYNGIIFFLK) inhibits ang-
iogenesis and metastasis through the disruption of FGF2 binding 
to the heparan sulfate side chain of CD44 (Hibino et al., 2004). 
Several peptides corresponding to regions of laminin-1 have been 
implicated in the regulation of angiogenesis and tumor metastasis 
(Malinda et al., 1999; Ponce and Kleinman, 2003). Akalu et al. 
(2007) have identified STQ peptide which recognize proteolysed 
or denatured laminin-1, but not intact laminin-1 or native and 
denatured laminin-5. STQ peptide inhibits endothelial and tumor 
cell adhesion, migration, proliferation in vitro and blocks angio-
genesis, tumor growth, and metastasis in vivo. Abnormal synthesis 
of the endothelial cell basement membrane components could 
also contribute to vascular leakage as shown in diabetic retina. 
It remains to be explored whether the basement membrane lam-
inin proteolysis and unmasking of cryptic sites, exert their effect 
on the maturation or destabilization of vascular walls in tumors 
(Oshitari et al., 2006).
During pathological angiogenesis such as in tumor angiogenesis 
and vascular diseases, specific cryptic type IV collagen epitopes are 
exposed. For instance, a cryptic site hidden within the 3D structure 
of type IV collagen is exposed by MMP2 and promotes tumor 
growth and angiogenesis in vivo (Xu et al., 2001). The recognition 
of a cryptic epitope (HU177) present exclusively in type IV col-
lagen by a specific mouse antibody (HUIV26) inhibits endothelial 
cell proliferation and tubule-like structure formation in vitro and 
tumor angiogenesis in vivo (Cretu et al., 2007). The type IV collagen 
epitope (HU177) is present in ECM of tumor blood vessels but 
not in quiescent vessels. Its inhibition results in the expression of 
the cell cycle inhibitor the cyclin-dependent kinase (CDK) inhibi-
tor p27kip1 in endothelial cells (Cretu et al., 2007). Interestingly, 
cryptic activities embedded within intact type IV collagen mol-
ecules are unmasked as a consequence of MT1-MMP, MT2-MMP, 
and MT3-MMP during morphogenesis (Rebustini et al., 2009). 
MT-MMPs activities release NC1 domains of type IV collagen 
and stimulate branching of cultured mouse submandibular gland 
(SMG) explants. In choroidal neovascularization (CNV), the ang-
iogenic process associated with age-related macular degeneration, 
exposure of cryptic collagen type IV epitopes is associated with 
increased CNV incidence. The humanized antibody H8 directed 
against a cryptic collagen type IV epitope inhibits CNV progression 
(Gocheva et al., 2006). However, more investigations are needed 
for a better understanding of the role of MT-MMPs on unmasking 
MT4-MMP and MT1-MMP play a major role in pericyte migration 
and recruitment to the vessels (Figure 2). These distinct effects of 
MT-MMPs in vessel wall function and integrity is of great interest 
in delivery of therapeutics in vivo. These two molecules are able 
to modify the tumor physiology and to affect vessel permeability 
in vivo. At this end, understanding, the cellular and the molecular 
mechanisms of MT-MMPs and their interaction with ECM and 
non-ECM molecules, permeability, and IFP of tumor, will open new 
targeting opportunities to enhance vascular leakage and delivery 
of therapeutics to tissues where hemodynamics limit efficient drug 
delivery (Figure 3).
It is well known that vessel destabilization is one of series of 
events during the angiogenic process. In addition, immature 
blood vessels in human tumors have been reported to regress 
as a consequence of VEGF withdrawal (Benjamin et al., 1999). 
Kazlauskas works have highlighted a new concept of vascular 
regression and show that is not merely a default of apoptosis. 
Instead, it is a response that is intrinsic to the angiogenic pro-
gram and is controlled by specific signaling enzymes (Im and 
Kazlauskas, 2006; Im et al., 2010). A subtle coordination change 
in tissue remodeling during angiogenesis and regression must 
occur during normal and pathological events. It is possible that 
vascular regression occurs as consequence of impaired vascular 
cell–ECM contact, and the role MT-MMPs may be important in 
this process. We cannot exclude that MT4-MMP induction of 
pericyte detachment from endothelial cells in tumor may drive 
the destabilization step of the angiogenic program (Chabottaux 
et al., 2009). More investigations are required to determine the 
exact role of MT4-MMP at all steps of the angiogenic process. 
MT1-MMP and MT4-MMP can be considered as angiomodulator 
which could control vessel maturation or regression. Therefore, 
vessel regression or maturation dependent-MT-MMPs would be 
potential diagnostic and/or therapeutic targets for vascular dis-
eases and tumor angiogenesis.
cryptIc sItes In vascular basement membrane
The vascular basement membrane is commonly considered as 
altered or incomplete in tumor associated blood vessels (Paku, 
1998). Structural analysis and immunoreactivities for basement 
membrane components (collagen type IV, laminin, entactin/
nidogen, and fibronectin) have been performed in various tumor 
mouse models including spontaneous RIP-Tag2 pancreatic islet 
tumors, MCa-IV mammary carcinomas, and Lewis lung carcinoma. 
These analyses revealed that basement membrane covers most 
tumor vessels, but it exhibits multiple abnormalities and incom-
plete association with endothelial cells and pericytes in these tumors 
(Baluk et al., 2003; Page-McCaw et al., 2007). Vessel basement 
membrane is considered as a reservoir for various growth factors, 
cytokines that are released by proteases during vascular response 
to physiological or pathological stimuli (Kessenbrock et al., 2010). 
In addition, some basement membrane cleavage products play a 
crucial role in vessel sprouting and vessel permeability.
Laminin is the major basement membrane ligand for epithe-
lial, endothelial, and carcinoma cells. It supports cell attachment, 
migration, and invasion through its interaction with two major 
receptors, α1β1 and α6β4 integrins (Nishiuchi et al., 2006). 
Laminin also contains several functional domains that can regu-
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and ECM like thrombospondin-1 modulate vessel integrity and 
progenitor cell recruitment in cardiovascular disease and ischemia 
(Silvestre et al., 2001; Favier et al., 2005; Smadja et al., 2011). 
Many similarities exist in the molecular and cellular alteration 
common to blood vessels in cancer and vascular diseases, such as 
arthrosclerosis, diabetic retinopathy, hypertension, and aneurism 
rupture. However, therapeutic benefits derived from ECM degrad-
ing enzyme inhibition may lead to vessel stabilization in cancer 
and hyperactive tissues. The complexity of targeting proteolytic 
enzymes due to their pro and anti-angiogenic function in cancer 
or vascular diseases (Lopez-Otin and Matrisian, 2007), renders 
targeting cryptic collagen sites a highly selective approach for 
regulating angiogenesis. Further investigations are required to 
understand how basement membrane molecules regulate vessel 
permeability and leakage in cancer and vascular diseases proc-
esses. Particularly, this may be beneficial if combined with other 
target pathway inhibitors or cytotoxic drugs for cancer treatment. 
An increased understanding of regulation and function of cryptic 
fragments within ECM and proteolytic peptides in the control of 
vascular cell physiology will likely lead to more effective strategies 
for therapy, which can be targeted specifically to tumor angio-
genesis or vascular pathologies.
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cryptic sites within type IV collagen of vessel basement membrane 
and its implication in vascular permeability/leakage in cancer and 
vascular diseases.
Perlecan, an additional widely expressed vascular basement 
membrane component plays an important role in angiogenesis 
and promotes endothelial cell migration (Aviezer et al., 1994). 
However, endorepellin, a fragment generated by the processing of 
the perlecan C-terminal domain by MMPs (Gonzalez et al., 2005), 
inhibits angiogenesis through its interaction with α1β1 and triggers 
a signaling cascade that leads to the disruption of actin cytoskel-
eton in endothelial cells and ultimately to angiostasis (Iozzo, 2005). 
Endorepellin can promote platelet response to collagen, clot forma-
tion, and healing, through distinct interaction with α2β1 receptor 
integrin (Bix et al., 2007).
The vascular basement membrane in tumor or vascular patholo-
gies is exposed to intensive remodeling by MMPs that can create 
a less restrictive microenvironment. MMPs release growth factors 
sequestered in the matrix or generate bioactive peptides that pro-
mote endothelial cell proliferation, motility, and new blood vessel 
growth. However, ECM proteolysis may release a number of endog-
enous angiogenesis inhibitors, including endostatin, tumstatin, and 
other fragments of ECM proteins that may have anti-angiogenic 
activity (Egeblad and Werb, 2002).
conclusIon
The ECM in vessel wall is no longer seen as a simple scaffold for 
vascular cells, but is now viewed as a dynamic actor in vascular 
cell signaling and physiology control. Deregulation of the bal-
ance in ECM synthesis and degradation contributes to vascular 
pathologies and tumor angiogenesis. Expression of MT-MMPs 
in tumor microenvironment results in blood vessel abnormali-
ties and dysfunctions. These molecules could also affect vascular 
wall destabilization and dysfunctions in vascular disorders. MMPs 
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